Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Las Vegas Sands Corp. (LVS) vs McKesson Corporation (MCK) Price & Performance

Las Vegas Sands Corp.Trade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

Las Vegas Sands Corp. vs McKesson Corporation — how do they compare? Las Vegas Sands Corp. trades at $45.69 (market cap $29.44B), while McKesson Corporation trades at $888.37 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 3.6× Las Vegas Sands Corp.'s market cap, and Las Vegas Sands Corp. pays the higher dividend (2.64%). Which is the better fit depends on your goals.

LVSMCK
Market Cap
$29.44B$105.14B
Sector
Consumer CyclicalHealth
52-Week High
$69.49$995.69
52-Week Low
$44.78$659.01
Enterprise Value
$41.33B$111.67B
Dividend Yield
2.64%0.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Las Vegas Sands Corp.

LVS trades at $45.68, up 0.48% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue grew to $13.02B in 2025, with net income of $1.63B and a 12.59% margin. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains strong profitability metrics, including a 48.52% gross margin and 134.29% ROE. Positive news includes ESG recognitions and community initiatives, supporting a stable operational outlook.

The stock presents a buy opportunity with a consensus price target of $60.75, implying 33% upside, backed by 59% analyst buy ratings. Risks include high debt levels, with a debt-to-asset ratio of 73.15% in 2025, and sensitivity to macroeconomic factors affecting the gaming and tourism sectors. Institutional sentiment remains positive, but investors should monitor debt management and regional economic conditions for sustained growth.

McKesson Corporation

McKesson (MCK) trades at $879.87, up 1.18% today, with strong momentum from recent earnings beats and raised guidance. The stock shows bullish technical signals, supported by robust revenue growth and solid cash flow generation. Recent news highlights strength in specialty drugs and oncology, driving positive sentiment.

Outlook remains favorable with a consensus price target of $990.67, though thin profit margins and high liabilities pose risks. Continued execution on growth initiatives and cost discipline are key for sustained upside, while macroeconomic pressures and competitive dynamics require monitoring.

Returns comparison

Trailing returns across standard periods

About Las Vegas Sands Corp.

Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.

Read more on LVS

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK